Friday 6 November 2026
Export ZBH’s income statement to Excel — free account
Zimmer Biomet Holdings, Inc.
ZBH Healthcare Medical Devices
Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.
- Revenue
- +3.07%
- EPS
- −13.5%
- Free cash flow
- +29.8%
- Total debt
- −7.50%
Quarter to September 2026, against a year earlier
105.28
1.57
−1.47%
Follow ZBH
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 6 | 6 | 6 |
+8 more TTM periods Free account |
| 6.02% | 6.41% | 6.07% | 5.60% | ||
| 3.26% | 3.53% | 3.39% | 3.17% | ||
ROIC |
3.66% | 3.82% | 3.74% | 3.50% | |
Return on Tangible Assets |
19.49% | 18.67% | 17.66% | 14.87% | |
Average Days of Receivables |
77.34 | 75.91 | 75.03 | 75.58 | |
Free Cash Flow per Share |
5.86 | 5.39 | 5.17 | 5.44 | |
Free Cash Flow |
1,116.20 | 1,036.50 | 1,008.10 | 1,077.30 | |
Capital Expenditures |
(768.40) | (706.80) | (665.60) | (619.80) | |
| Other line items | |||||
Cash ROIC |
5.41% | 5.05% | 4.90% | 5.18% | |
Accounts Receivable Turnover |
5.02 | 5.03 | 5.16 | 5.17 | |
Accounts Payable Turnover |
7.72 | 7.31 | 7.61 | 10.02 | |
Inventory Turnover |
1.07 | 1.09 | 1.12 | 1.10 | |
Average Days of Payables |
0.00 | 50.18 | 52.31 | 44.35 | |
Days of Inventory on Hand |
332.50 | 323.27 | 325.42 | 334.66 | |
Tax Rate |
(0.13) | (0.14) | (0.16) | (0.15) | |
Research and Development Expense of Revenue |
5.05% | 5.20% | 5.37% | 5.57% | |
Selling, General and Administrative Expense of Revenue |
40.56% | 40.34% | 39.82% | 39.57% | |
Share Based Compensation of Revenue |
1.13% | 1.15% | 1.13% | 1.10% | |
Interest Coverage |
4.03 | 4.17 | 3.99 | 3.75 | |
Operating CF/Net income |
2.46 | 2.16 | 2.20 | 2.41 | |
Depreciation/Fixed assets |
0.48 | 0.50 | 0.50 | 0.50 | |
Capex/Depreciation |
(0.69) | (0.64) | (0.60) | (0.57) | |
Revenue per Share |
44.99 | 44.27 | 43.12 | 41.57 | |
Operating CF per Share |
9.89 | 9.07 | 8.58 | 8.57 | |
Capex per Share |
(4.03) | (3.68) | (3.41) | (3.13) | |
Capex to Sales |
0.09 | 0.08 | 0.08 | 0.08 |
Columns are period end dates · fundamentals updated 5 Nov 2026